NCT04651829

Brief Summary

Cow's milk protein allergy (CMPA) is often evoked in infants, in particular in front of delayed symptoms such as rectal bleeding, atopic dermatitis, excessive crying, reflux, failure to thrive... But in case of non IgE-mediated CMPA, the only way to diagnose this allergy is to proceed to an elimination-reintroduction test over a period of 2 to 4 weeks, to improve symptoms first, and then provoke them. Even if the diagnosis is confirmed, we speculate that non IgE-mediated CMPA has a faster resolution than other CMPA. The first aim of this study is to estimate the prevalence of non IgE-mediated CMPA in a cohort of infants with delayed symptoms which could be relied to a CMPA. The second goal is evaluate the age of tolerance in non IgE-mediated CMPA with oral food challenge for milk ever 2 months after 4 months of age.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started May 2014

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2014

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2014

Completed
3.6 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2017

Completed
3 years until next milestone

First Submitted

Initial submission to the registry

November 26, 2020

Completed
7 days until next milestone

First Posted

Study publicly available on registry

December 3, 2020

Completed
Last Updated

December 3, 2020

Status Verified

November 1, 2020

Enrollment Period

Same day

First QC Date

November 26, 2020

Last Update Submit

November 26, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • prevalence of CMPA in patients with suspicion of non IgE-mediated CMPA

    We proceed to an elimination-reintroduction test of the culprit food (CMP) in patients with delayed symptoms of non IgE-mediated CMPA (rectal bleeding, atopic dermatitis, reflux, excessive crying, failure to thrive...) after a period of two to eight weeks of exclusion of CMP. If symptoms disappear after CMP elimination, and reappear after CMP reintroduction, the diagnosis of CMPA is confirmed.

    2 to 8 weeks after inclusion

Secondary Outcomes (1)

  • age of tolerance of confirmed non IgE-mediated CMPA

    after 4 months of age, and at least after 2 months of elimination diet, and then ever 2 months until tolerance

Interventions

First oral food challenge after a short period of several weeks of avoidance of CMP to confirm diagnosis of CMPA

Second oral food challenge to test tolerance after 4 months of age if confirmed CMPA

Eligibility Criteria

AgeUp to 4 Months
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

All infants under 4 months of age consulting for delayed symptoms evoking CMPA are prospectively included. All these infants benefit from a CMP elimination diet by replacing their usual formula with an extensive CMP hydrolysate, hydrolysed rice-protein formula, or an amino acid-based formula (AAF). Only children whose symptoms disappear after this exclusion diet are selected for the study.

You may qualify if:

  • infants under 4 months age with delayed symptoms evoking CMPA

You may not qualify if:

  • exclusively breastfed infants
  • no improvement of symptoms despite amino acid formula
  • patients with symptoms of food protein induced enterocolitis
  • patients who do not have diagnostic oral food challenge within 3 months after the start of elimination diet

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Pediatric nutrition and gastroenterology department, Trousseau Hospital, APHP

Paris, 75012, France

Location

MeSH Terms

Conditions

ProctocolitisDermatitis, AtopicGastroesophageal Reflux

Condition Hierarchy (Ancestors)

ColitisGastroenteritisGastrointestinal DiseasesDigestive System DiseasesProctitisColonic DiseasesIntestinal DiseasesSigmoid DiseasesRectal DiseasesSkin Diseases, GeneticGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesDermatitisSkin DiseasesSkin and Connective Tissue DiseasesSkin Diseases, EczematousHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEsophageal Motility DisordersDeglutition DisordersEsophageal Diseases

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr, MD

Study Record Dates

First Submitted

November 26, 2020

First Posted

December 3, 2020

Study Start

May 1, 2014

Primary Completion

May 1, 2014

Study Completion

December 1, 2017

Last Updated

December 3, 2020

Record last verified: 2020-11

Locations